T C Skaar
Overview
Explore the profile of T C Skaar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henry N, Unger J, Vaidya R, Darke A, Skaar T, Fisch M, et al.
Contemp Clin Trials
. 2024 Oct;
147:107712.
PMID: 39395534
Background: Premenopausal women with early stage, high risk hormone receptor positive breast cancer are at risk of early discontinuation of adjuvant endocrine therapy (ET), primarily because of toxicity, which can...
2.
Hertz D, Kidwell K, Hilsenbeck S, Oesterreich S, Osborne C, Philips S, et al.
Breast Cancer Res Treat
. 2017 Jul;
166(1):277-287.
PMID: 28730340
Purpose: A number of studies have tested the hypothesis that breast cancer patients with low-activity CYP2D6 genotypes achieve inferior benefit from tamoxifen treatment, putatively due to lack of metabolic activation...
3.
Cavallari L, Beitelshees A, Blake K, Dressler L, Duarte J, Elsey A, et al.
Clin Transl Sci
. 2017 Mar;
10(3):143-146.
PMID: 28294551
No abstract available.
4.
Ipe J, Swart M, Burgess K, Skaar T
Clin Transl Sci
. 2017 Feb;
10(2):67-77.
PMID: 28213901
No abstract available.
5.
Hicks J, Sangkuhl K, Swen J, Ellingrod V, Muller D, Shimoda K, et al.
Clin Pharmacol Ther
. 2016 Dec;
102(1):37-44.
PMID: 27997040
No abstract available.
6.
Hertz D, Kidwell K, Seewald N, Gersch C, Desta Z, Flockhart D, et al.
Pharmacogenomics J
. 2016 Aug;
17(6):521-527.
PMID: 27549341
Discovery of clinical and genetic predictors of exemestane pharmacokinetics was attempted in 246 postmenopausal patients with breast cancer enrolled on a prospective clinical study. A sample was collected 2 h...
7.
Eadon M, Desta Z, Levy K, Decker B, Pierson R, Pratt V, et al.
Clin Pharmacol Ther
. 2016 Feb;
100(1):63-6.
PMID: 26850569
Hospital systems increasingly utilize pharmacogenomic testing to inform clinical prescribing. Successful implementation efforts have been modeled at many academic centers. In contrast, this report provides insights into the formation of...
8.
Hicks J, Bishop J, Sangkuhl K, Muller D, Ji Y, Leckband S, et al.
Clin Pharmacol Ther
. 2015 May;
98(2):127-34.
PMID: 25974703
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and...
9.
Burgess K, Philips S, Benson E, Desta Z, Gaedigk A, Gaedigk R, et al.
Clin Pharmacol Ther
. 2015 May;
98(2):205-15.
PMID: 25968989
Developmental changes in the liver can significantly impact drug disposition. Due to the emergence of microRNAs (miRNAs) as important regulators of drug disposition gene expression, we studied age-dependent changes in...
10.
Levy K, Decker B, Carpenter J, Flockhart D, Dexter P, Desta Z, et al.
Clin Pharmacol Ther
. 2014 May;
96(3):307-9.
PMID: 24807457
Pharmacogenomics (PGx) technology is advancing rapidly; however, clinical adoption is lagging. The Indiana Institute of Personalized Medicine (IIPM) places a strong focus on translating PGx research into clinical practice. We...